All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Grants Fast Track Designation to ITM-11 for Gastroenteropancreatic Neuroendocrine Tumors

October 28th 2022

The FDA has granted a fast track designation to 177Lu-edotreotide for use as a potential therapeutic option in patients with gastroenteropancreatic neuroendocrine tumors.

MOUNTAINEER Data Confirm Clinical Benefit of Tucatinib Plus Trastuzumab in HER2+ mCRC

October 28th 2022

Additional analyses of the phase 2 MOUNTAINEER trial further support the early administration of tucatinib in combination with trastuzumab as an optimal treatment strategy for patients with previously treated HER2-positive metastatic colorectal cancer.

Study Shows Gene Expression in Cancerous Bladder Tumors Differs by Race

October 28th 2022

A new study led by Cedars-Sinai Cancer investigators shows for the first time that gene expression differs by race in patients with high-risk non-muscle-invasive bladder cancer.

NVL-520 Demonstrates Preliminary Clinical Activity in ROS1-Positive NSCLC

October 28th 2022

The novel brain-penetrant ROS1-selective inhibitor NVL-520 elicited clinical activity and was well tolerated in heavily pretreated patients with ROS1 fusion–positive non–small cell lung cancer.

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Whom to Treat?

October 28th 2022

PARP inhibitors have emerged as agents that generate improved oncological outcomes in select patient populations with metastatic castration-resistant prostate cancer.

Cilta-cel Induces Strong Response in Chinese Patients With Relapsed/Refractory Multiple Myeloma

October 28th 2022

Ciltacabtagene autoleucel produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma treated at 8 sites in China.

Darolutamide Combination Improves OS vs Placebo in Black Patients With mHSPC

October 28th 2022

Darolutamide plus androgen-deprivation therapy and docetaxel elicited an overall survival benefit over placebo plus ADT and docetaxel in Black and African American patients with metastatic hormone-sensitive prostate cancer similar to the benefit observed in the overall population of the ARASENS trial.

Neoadjuvant Systemic Therapy Followed by Image-Guided Biopsy Lessens Surgical Need in Early-Stage Breast Cancer

October 27th 2022

Carefully selected patients with triple-negative or HER2-positive breast cancer who demonstrated pathologic complete responses to neoadjuvant systemic therapy as predicted by image-guided vacuum-assisted core biopsy avoided breast surgery and went on to standard radiotherapy.

IMC-F106C Shows Potential as T-cell Receptor–Driven Therapy in Melanoma

October 27th 2022

Omid Hamid, MD, highlights the importance of evaluating PRAME×CD3 Immune-mobilizing T cell receptor against cancer for melanoma treatment, the key benefits provided to patients through improved disease control and circulating tumor DNA reduction, and the safety profile of the therapy.

Radiation Plus Intermittent Hormone Therapy Improves PFS in Oligometastatic Prostate Cancer

October 27th 2022

A regimen comprised of radiation and intermittent hormone therapy (HT) resulted in an improvement in progression-free survival in patients with oligometastatic prostate cancer, according to data from the phase 2 EXTEND trial.

FDA Raises Questions About BLA for Omburtamab in Pediatric Metastatic Neuroblastoma

October 27th 2022

The FDA has expressed concern about the efficacy of 131I-omburtamab prior to a meeting of the regulatory agency’s ODAC to examine data supporting the BLA seeking the agent’s approval for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

Trastuzumab Deruxtecan Could Challenge Frontline Trastuzumab/Pertuzumab Combo in HER2+ Breast Cancer

October 27th 2022

Sara A. Hurvitz, MD, discusses the evolving treatment paradigm in HER2-positive breast cancer, ongoing research in the space, and developments in the treatment of triple-negative breast cancer.

Fred Hutch Hosts Inaugural Dr E. Donnall Thomas Symposium

October 27th 2022

Leading researchers from around the globe visited Fred Hutchinson Cancer Center to honor Dr E. Donnall Thomas and to discuss the future of transplantation, gene, and cellular therapies at the inaugural Dr E. Donnall Thomas Symposium.

Antidrug Antibodies Against Atezolizumab Associated With Poor Outcomes in HCC

October 27th 2022

Highly elevated levels of antidrug antibodies against atezolizumab were associated with poorer clinical outcomes for patients who received atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

OS Advances Gather Steam in Breast Cancer

October 27th 2022

The treatment of patients with breast cancer is making noteworthy strides in several clinical settings, with recent trial results showing overall survival improvements for advanced and metastatic disease.

Time Required to Address Scientific Questions Generates an Information Dilemma

October 26th 2022

One of the more perplexing issues surrounding scientific questions is the extended time required to provide an answer. Even once a well-considered and vetted conclusion is obtained, an additional interval of time may be required to modify or reverse the answer because of new, relevant data.

Capivasertib Plus Fulvestrant Yields PFS Improvement in HR+ Locally Advanced or Metastatic Breast Cancer

October 26th 2022

Capivasertib plus fulvestrant generated a statistically and clinically significant improvement in progression-free survival in select patients with hormone receptor–positive, HER2-low or -negative, locally advanced or metastatic breast cancer.

Preclinical Study: Three-Step Treatment Strategy for Pancreatic Cancer

October 26th 2022

Cedars-Sinai cancer study shows novel strategy disrupts the difficult-to-treat tumor microenvironment, preventing cancer from spreading.

Taletrectinib Shows Promising ORR and Tolerability in ROS1+ NSCLC

October 26th 2022

Misako Nagasaka, MD, PhD, discusses the various needs taletrectinib meets in the ROS1-positive population, initial efficacy data with the agent, and its impressive safety profile.

Melphalan Flufenamide Plus Daratumumab Elicits PFS Benefit in Relapsed/Refractory Myeloma

October 26th 2022

The combination of melphalan flufenamide and daratumumab plus hyaluronidase-fihj and dexamethasone improved progression-free survival over daratumumab and dexamethasone alone in select patients with relapsed/refractory multiple myeloma.